Correction of a release from 01.07.2019, 16:16 CET/CEST - Sartorius Stedim Biotech SA: HALF-YEAR report of the liquidity contract with the stockbroker company Gilbert Dupont

Sartorius Stedim Biotech SA Correction of a release from 01.07.2019, 16:16 CET/CEST - Sartorius Stedim Biotech SA: HALF-YEAR report of the liquidity contract with the stockbroker company Gilbert Dupont 02-Jul-2019 / 12:08 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Sartorius Stedim Biotech S.A. - 13781 Aubagne,France     Half-yearreport of the liquidity contract with the stockbroker company Gilbert Dupont   Aubagne, France | July 2, 2019   This announcement contains corrections of the figures given in our half-year report of the liquidity contract published yesterday.   Under the liquidity contract concluded between SARTORIUSSTEDIM BIOTECH and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account on June 28, 2019:   Number of shares: 2,519 Liquidity account cash balance: EUR468,433.16   During the first half of 2019, the following were negotiated:   ORDER INTAKE 72,168securities EUR7,778,802.43 2,404 transactions SALES 73,065securities EUR7,889,953.10 2,522 transactions     Itshould be noted that in the second half of 2018, which ended December 31, 2018, the following assets appeared on the liquidity account:   Number of shares: 3,416 Liquidity account cash balance: EUR357,282.50     It should also be noted that upon implementing the liquidity contract, the following assets were made available:   Number of shares: 654 Liquidity account cash balance: EUR394,895.12     A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2018, the company earned sales revenue of EUR1,212.2 million and currently employs some 5,800 people. _________________________________________________________________________________________   Contact Ben Orzelek Investor Relations +49(0)551.308.1668 [e-mail]     Sartorius Stedim Biotech SA Z.I. Les Paluds Avenue de Jouques, CS 91051 13781 Aubagne Cedex, France Phone: [phone] Fax: [phone] www.sartorius-stedim.com   Regulatory filing PDF file Document title: HALF-YEAR report of the liquidity contract with the stockbroker company Gilbert Dupont Document: http://n.eqs.com/c/fncls.ssp?u=CRTGAYKIHJ

Language:	English
Company:	Sartorius Stedim Biotech SA
	Avenue de Jouques
	13781 Aubagne
	France
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.sartorius-stedim.com
ISIN:	FR0013154002
Euronext Ticker:	DIM
AMF Category:	Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID:	834751

End of Announcement	EQS News Service

834751  02-Jul-2019 CET/CEST